{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:56:10Z","timestamp":1777985770517,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10147-023-02377-z","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T04:01:50Z","timestamp":1691812910000},"page":"1298-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022"],"prefix":"10.1007","volume":"28","author":[{"given":"Hiroyuki","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamitsu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-1551","authenticated-orcid":false,"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The committee of Clinical practice guidelines for the management of kidney disease during anticancer drug therapy 2022","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"2377_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/ijms21228582","volume":"21","author":"M Gudowska-Sawczuk","year":"2020","unstructured":"Gudowska-Sawczuk M, Kudelski J, Mroczko B (2020) The role of chemokine receptor CXCR3 and Its ligands in renal cell carcinoma. Int J Mol Sci 21:334","journal-title":"Int J Mol Sci"},{"key":"2377_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","volume":"10","author":"TJ Velenosi","year":"2014","unstructured":"Velenosi TJ, Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol 10:1131\u20131143","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2377_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.kint.2020.06.046","volume":"98","author":"C Porta","year":"2020","unstructured":"Porta C, Bamias A, Danesh FR et al (2020) KDIGO Controversies on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int 98:1108\u20131119","journal-title":"Kidney Int"},{"key":"2377_CR4","first-page":"382","volume":"7","author":"DL Giusti","year":"1973","unstructured":"Giusti DL, Hayton WL (1973) Dosage regimen adjustments in renal impairment. Drug Intell Clin Pharm 7:382\u2013387","journal-title":"Drug Intell Clin Pharm"},{"key":"2377_CR5","unstructured":"US. Food and Drug Administration Publication. 2020 Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and."},{"key":"2377_CR6","unstructured":"European Medicines Agency. 2016 Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function, https:\/\/www.ema.europa.eu\/en\/evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function-scientific."},{"key":"2377_CR7","unstructured":"The Japanese society of Nephrology and pharmacotherapy. List of Drug Administration Methods by Renal Function [Japanese]. Japanese Journal of Nephrology and Pharmacotherapy. 10: 216\u2013303"},{"key":"2377_CR8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA et al (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898\u2013903","journal-title":"Clin Pharmacol Ther"},{"key":"2377_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/1389200220666190402143125","volume":"20","author":"K Fujita","year":"2019","unstructured":"Fujita K, Matsumoto N, Ishida H et al (2019) Decreased disposition of anticancer drugs predominantly eliminated via the liver in patients with renal failure. Curr Drug Metab 20:361\u2013376","journal-title":"Curr Drug Metab"},{"key":"2377_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"2377_CR11","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA et al (2019) Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 20:e200\u2013e207","journal-title":"Lancet Oncol"},{"key":"2377_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02382-2","author":"Y Ando","year":"2023","unstructured":"Ando Y, Nishiyama H, Shimodaira H et al. (2023) Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-023-02382-2","journal-title":"Int J Clin Oncol"},{"key":"2377_CR13","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","volume":"21","author":"CH Takimoto","year":"2003","unstructured":"Takimoto CH, Remick SC, Sharma S et al (2003) Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a national cancer institute organ dysfunction working group study. J Clin Oncol 21:2664\u20132672","journal-title":"J Clin Oncol"},{"key":"2377_CR14","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-07-0475","volume":"13","author":"CH Takimoto","year":"2007","unstructured":"Takimoto CH, Graham MA, Lockwood G et al (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13:4832\u20134839","journal-title":"Clin Cancer Res"},{"key":"2377_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","volume":"79","author":"Y Nishikawa","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T et al (2017) Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79:629\u2013633","journal-title":"Cancer Chemother Pharmacol"},{"key":"2377_CR16","unstructured":"TAIHO Phamaceutical Co., Ltd. TS-1\u00ae. Guide to Proper Use, https:\/\/www.taiho.co.jp\/medical\/brand\/ts-1\/guide\/gu_04-3.html [In Japanese] reference. Accessed 15 Aug 2022"},{"key":"2377_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/cas.14758","volume":"112","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Imamura CK, Booka E et al (2021) Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application. Cancer Sci 112:751\u2013759","journal-title":"Cancer Sci"},{"key":"2377_CR18","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1172\/JCI107362","volume":"52","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804\u20131811","journal-title":"J Clin Invest"},{"key":"2377_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372\u2013380","journal-title":"Cancer Chemother Pharmacol"},{"key":"2377_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13318-016-0359-9","volume":"42","author":"S Wiebe","year":"2017","unstructured":"Wiebe S, Schnell D, K\u00fclzer R et al (2017) Influence of renal impairment on the pharmacokinetics of afatinib: an open-label, single-dose study. Eur J Drug Metab Pharmacokinet 42:461\u2013469","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2377_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","volume":"21\u201322","author":"AV Kamath","year":"2016","unstructured":"Kamath AV (2016) Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol 21\u201322:75\u201383","journal-title":"Drug Discov Today Technol"},{"key":"2377_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bcp.12988","volume":"82","author":"B Zhao","year":"2016","unstructured":"Zhao B, Chen R, O\u2019Connor OA et al (2016) Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol 82:696\u2013705","journal-title":"Br J Clin Pharmacol"},{"key":"2377_CR23","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"2377_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"2377_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson K, Ismaila N, Flynn PJ et al (2018) Role of bone-modifying agents in multiple myeloma: american society of clinical oncology clinical practice guideline update. J Clin Oncol 36:812\u2013818","journal-title":"J Clin Oncol"},{"key":"2377_CR26","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835","journal-title":"J Bone Miner Res"},{"key":"2377_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L et al (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"2377_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J et al (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4\u20135. Am J Nephrol 41:129\u2013137","journal-title":"Am J Nephrol"},{"key":"2377_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.nefro.2016.02.007","volume":"36","author":"P Monge Rafael","year":"2016","unstructured":"Monge Rafael P, Arias M, Fern\u00e1ndez-Fresnedo G (2016) Severe hypocalcemia following denosumab injection in patient with chronic kidney disease. Nefrologia 36:446\u2013448","journal-title":"Nefrologia"},{"key":"2377_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358","journal-title":"JAMA"},{"key":"2377_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","volume":"43","author":"J Chen","year":"2021","unstructured":"Chen J, Zhou L, Liu X et al (2021) Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm 43:2\u201310","journal-title":"Int J Clin Pharm"},{"key":"2377_CR32","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang HM, Okwuosa TM, Scarabelli T et al (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552\u20132565","journal-title":"J Am Coll Cardiol"},{"key":"2377_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","volume":"20","author":"M Agarwal","year":"2018","unstructured":"Agarwal M, Thareja N, Benjamin M et al (2018) Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep 20:65","journal-title":"Curr Oncol Rep"},{"key":"2377_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/MNH.0000000000000197","volume":"25","author":"L Saleh","year":"2016","unstructured":"Saleh L, Danser JA, van den Meiracker AH (2016) Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment. Curr Opin Nephrol Hypertens 25:94\u201399","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2377_CR35","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the esc committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 37:2768\u20132801","journal-title":"Eur Heart J"},{"key":"2377_CR36","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S et al (2019) The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res 42:1235\u20131481","journal-title":"Hypertens Res"},{"key":"2377_CR37","first-page":"381","volume":"42","author":"N Sofue","year":"2016","unstructured":"Sofue N, Iwai M, Usami E et al (2016) Analysis of the risk factors for onset of proteinuria with bevacizumab administration and the effect of renin-angiotensin system depressant drugs. Iryo Yakugaku. 42:381\u2013386","journal-title":"Iryo Yakugaku."},{"key":"2377_CR38","doi-asserted-by":"publisher","first-page":"102947","DOI":"10.1016\/j.critrevonc.2020.102947","volume":"150","author":"C Labaki","year":"2020","unstructured":"Labaki C, Rawadi E, Chebel R et al (2020) Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. Crit Rev Oncol Hematol 150:102947","journal-title":"Crit Rev Oncol Hematol"},{"key":"2377_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mds344","volume":"24","author":"N Janus","year":"2013","unstructured":"Janus N, Launay-Vacher V, Thyss A et al (2013) Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24:501\u2013507","journal-title":"Ann Oncol"},{"key":"2377_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10120-015-0536-6","volume":"19","author":"E Booka","year":"2016","unstructured":"Booka E, Imamura CK, Takeuchi H et al (2016) Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. Gastric Cancer 19:876\u2013886","journal-title":"Gastric Cancer"},{"key":"2377_CR41","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","volume":"18","author":"AP Venook","year":"2000","unstructured":"Venook AP, Egorin MJ, Rosner GL et al (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780\u20132787","journal-title":"J Clin Oncol"},{"key":"2377_CR42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1211\/0022357022241","volume":"55","author":"T Eriksson","year":"2003","unstructured":"Eriksson T, H\u00f6glund P, Turesson I et al (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55:1701\u20131706","journal-title":"J Pharm Pharmacol"},{"key":"2377_CR43","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N et al (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34:1544\u20131557","journal-title":"J Clin Oncol"},{"key":"2377_CR44","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","volume":"166","author":"LM Wilson","year":"2017","unstructured":"Wilson LM, Rebholz CM, Jirru E et al (2017) Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 166:649\u2013658","journal-title":"Ann Intern Med"},{"key":"2377_CR45","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","volume":"10","author":"K Kunizawa","year":"2020","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J et al (2020) Denosumab for dialysis patients with osteoporosis: A cohort study. Sci Rep 10:2496","journal-title":"Sci Rep"},{"key":"2377_CR46","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1111\/ajt.14238","volume":"17","author":"JC Krisl","year":"2017","unstructured":"Krisl JC, Doan VP (2017) Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients. Am J Transplant 17:1974\u20131991","journal-title":"Am J Transplant"},{"key":"2377_CR47","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","volume":"71","author":"DE Tsai","year":"2001","unstructured":"Tsai DE, Hardy CL, Tomaszewski JE et al (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076\u20131088","journal-title":"Transplantation"},{"key":"2377_CR48","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/tri.12638","volume":"28","author":"CM Hope","year":"2015","unstructured":"Hope CM, Krige AJ, Barratt A et al (2015) Reductions in immunosuppression after haematological or solid organ cancer diagnosis in kidney transplant recipients. Transpl Int 28:1332\u20131335","journal-title":"Transpl Int"},{"key":"2377_CR49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.07087.x","volume":"154","author":"CC Otley","year":"2006","unstructured":"Otley CC, Berg D, Ulrich C et al (2006) Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 154:395\u2013400","journal-title":"Br J Dermatol"},{"key":"2377_CR50","doi-asserted-by":"publisher","first-page":"4369574","DOI":"10.1155\/2016\/4369574","volume":"2016","author":"H Holdaas","year":"2016","unstructured":"Holdaas H, De Simone P, Zuckermann A (2016) Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant 2016:4369574","journal-title":"J Transplant"},{"key":"2377_CR51","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.tp.0000280549.93403.dd","volume":"84","author":"J Gomez-Camarero","year":"2007","unstructured":"Gomez-Camarero J, Salcedo M, Rincon D et al (2007) Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 84:786\u2013791","journal-title":"Transplantation"},{"key":"2377_CR52","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/ctr.12430","volume":"28","author":"E Thimonier","year":"2014","unstructured":"Thimonier E, Guillaud O, Walter T et al (2014) Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant 28:1339\u20131348","journal-title":"Clin Transplant"},{"key":"2377_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.transproceed.2009.11.017","volume":"42","author":"C Chiurchiu","year":"2010","unstructured":"Chiurchiu C, Carre\u00f1o CA, Schiavelli R et al (2010) Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 42:277\u2013279","journal-title":"Transplant Proc"},{"key":"2377_CR54","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.transproceed.2009.06.040","volume":"41","author":"E Gonz\u00e1lez","year":"2009","unstructured":"Gonz\u00e1lez E, Andr\u00e9s A, Polanco N et al (2009) Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. Transplant Proc 41:2332\u20132333","journal-title":"Transplant Proc"},{"key":"2377_CR55","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/curroncol28010064","volume":"28","author":"L Kasherman","year":"2021","unstructured":"Kasherman L, Doi J, Karakasis K et al (2021) Angiogenesis inhibitors as anti-cancer therapy following renal transplantation: a case report and review of the literature. Curr Oncol 28:661\u2013670","journal-title":"Curr Oncol"},{"key":"2377_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S1368-7646(03)00005-0","volume":"6","author":"A Sparreboom","year":"2003","unstructured":"Sparreboom A, Danesi R, Ando Y et al (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6:71\u201384","journal-title":"Drug Resist Updat"},{"key":"2377_CR57","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","volume":"99","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Chebib FT, Cornell LD et al (2015) Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplantation 99:2382\u20132386","journal-title":"Transplantation"},{"key":"2377_CR58","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.4103\/0973-1482.168996","volume":"11","author":"FY M\u00fcsri","year":"2015","unstructured":"M\u00fcsri FY, Mutlu H, Ery\u0131lmaz MK et al (2015) Experience of bevacizumab in a patient with colorectal cancer after renal transplantation. J Cancer Res Ther 11:1018\u20131020","journal-title":"J Cancer Res Ther"},{"key":"2377_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2021.01.038","volume":"148","author":"LS Nguyen","year":"2021","unstructured":"Nguyen LS, Ortuno S, Lebrun-Vignes B et al (2021) Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Eur J Cancer 148:36\u201347","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02377-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:09:09Z","timestamp":1695964149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02377-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2377"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02377-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.N has received honoraria from MSD K.K., Astellas pharma Inc., and Merck Biopharma Co., Ltd., research fundings from Chugai Pharmaceutical Co. Ltd., and a scholarship donation from Bayer AG. H. Kitamura has received honoraria from Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Bayer AG, and Janssen Pharmaceutical K.K., and scholarship donations from Takeda Pharmaceutical Company Limited and Bayer AG. J.H has received honoraria from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Ono Pharm, AstraZeneca and Astellas Pharma Inc, and a research grant from Otsuka Pharmaceutical Co., Ltd. M. Yanagita has received honoraria from Astellas Pharma Inc, AstraZeneca, Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., Bayer AG, and Mitsubishi Tanabe Pharma, and research grants from Mitsubishi Tanabe Pharma, Boehringer Ingelheim International GmbH, and scholarship donations from Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}